← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Invesco Biotechnology & Genome ETF PBE $429M	82	+12	+17%	$131M
27	NSTG 27 DELISTED NanoString Technologies, Inc. NSTG	60	+1	+2%	$187M
28	28 Lineage Cell Therapeutics LCTX $250M	59	+2	+4%	$114M
29	BLCM 29 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	55	+55	–	$308M
30	30 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	53	+1	+2%	$51.1M
31	31 Arbutus Biopharma ABUS $850M	49	+1	+2%	$65.5M
32	AGTC 32 DELISTED Applied Genetic Technologies Corporation AGTC	48	+6	+14%	$191M
33	33 Veracyte VCYT $3.57B	48	-5	-9%	$91.2M
34	ATHX 34 DELISTED Athersys, Inc. Common Stock ATHX	47	-1	-2%	$12M
35	35 DELISTED Carisma Therapeutics CARM	41	-1	-2%	$159M
36	36 Atara Biotherapeutics ATRA $96.9M	39	+39	–	$172M
37	37 Opus Genetics IRD $337M	38	+7	+23%	$5.65M
38	38 Fortress Biotech FBIO $63.7M	36	-3	-8%	$19.2M
39	39 ProQR Therapeutics PRQR $205M	35	+5	+17%	$173M
40	40 Vericel Corp VCEL $2.1B	35	+4	+13%	$32.3M
41	41 Imunon IMNN $5.95M	33	-1	-3%	$7.58M
42	42 Pluri PLUR $11.9M	29	+2	+7%	$3.19M
43	43 uniQure QURE $1.56B	28	+2	+8%	$56.6M
44	44 Fate Therapeutics FATE $231M	23	+1	+5%	$51.7M
45	45 Neurogene NGNE $479M	22	0	0%	$31.2M
46	46 CareDx CDNA $3.45B	19	-3	-14%	$33.5M
47	47 DELISTED BioLife Solutions BLFS	15	0	0%	$1.02M
48	48 Ocugen OCGN $276M	13	+13	–	$60.9M
49	49 Abeona Therapeutics ABEO $266M	11	+11	–	$19.5M
50	50 DELISTED BRAINSTORM CELL THERAPUTC BCLI	11	+4	+57%	$488K